IBRX
NASDAQ · Biotechnology
Immunitybio Inc
$7.64
+0.32 (+4.37%)
IBRX News9 articles
ImmunityBio Faces Key Warrant Expiry Test on July 24 After Friday Rebound
ImmunityBio (NASDAQ:IBRX) faces a crucial warrant expiry on July 24, with up to 6.4 million shares potentially exercised, testing trading liquidity after a Friday rebound.
ImmunityBio Volume Surges on Russell Index Changes; Monday Trading Key
ImmunityBio surged 11.8% on Friday with volume tripling its average, driven by Russell index reconstitution. Monday's trading will reveal if the spike holds.
ImmunityBio Jumps on Russell Index Rebalancing and High Valuation
ImmunityBio surged 9.2% to $8.51 as its market cap exceeded the Russell 1000 cutoff, drawing buyers ahead of index reconstitution.
ImmunityBio's Anktiva Expansion Faces FDA Scrutiny with 2027 Decision Date
ImmunityBio's supplemental BLA for Anktiva in papillary-only bladder cancer has been accepted by the FDA, with a decision expected by Jan. 6, 2027. The company's stock traded at $7.76, down 2.8%.
ImmunityBio Secures Exclusive US Rights to Japan BCG Strain for Bladder Cancer
ImmunityBio announced exclusive U.S. rights to Japan BCG Laboratory's Tokyo-172 BCG strain for bladder cancer therapy, with FDA discussions planned. Shares closed at $7.97 Friday, down 2.2%.
ImmunityBio Surges on NK-Cell Manufacturing Milestone, Anktiva Expansion Progress
ImmunityBio shares jumped 10.5% Friday following news of a completed scalable manufacturing process for its NK-cell therapy platform and regulatory progress for its drug Anktiva. The company also reported surging 2025 revenue.
ImmunityBio Shares Dip Ahead of Key Business Update Call
ImmunityBio shares edged lower in premarket activity Tuesday, giving back some of the prior session's gains ahead of a scheduled business update and full-year results call later in the day.
ImmunityBio Shares Stabilize After 15% Surge, Focus Turns to Upcoming Earnings
ImmunityBio's stock held steady near $7 in premarket trading following a sharp 14.6% rally. Investors are now awaiting the company's quarterly results, due in early March.
ImmunityBio Secures Patents and BCG Supply Deal for Bladder Cancer Therapy
ImmunityBio announced five U.S. patents protecting its Anktiva-plus-BCG bladder cancer therapy through 2035, and an exclusive supply deal for the Tokyo-172 BCG strain.